entertainment -WSS

entertainment

author：leisure time 2025-09-28 23:47:24 - browse：1

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： How to convince healthy people to buy insurance

WSS

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Coloradans with cystic fibrosis could lose access to Trikafta

'Screen and refer' systems are hurting patients

Drug cartel violence flares in western Mexico after vigilante leader's killing

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Inari Medical to buy amputation prevention company LimFlow

focus

entertainment

hotspot

Activists slam private health insurers over coverage restrictions

After Sarepta trial failure, Duchenne families brace for more debate

Medicare proposal to cover medical devices draws a mixed reaction

Hubble vs. James Webb telescope images: See the difference

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Gene therapy’s promise and the high cost of hope

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Crowdfunding for unproven stem cell procedures spreads misinformation

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A letter from the executive editor: The 2023 STATUS List

Wikipedia

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

STAT wants to know your pick for a great summer read or listen

Explaining an after

Lupron, used to halt puberty in children, may cause lasting health problems

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

STAT wants to know your pick for a great summer read or listen

hotspot

entertainment

focus

focus